Search results
Key Points. This study found that the overall risk of breast cancer among hormonal contraceptive users is low. Because of the low baseline risks in the age groups using hormonal contraception (ie, premenopausal women), the risk difference between hormonal contraception users and nonusers is small.
7 gru 2017 · The overall absolute increase in breast cancers diagnosed among current and recent users of any hormonal contraceptive was 13 (95% CI, 10 to 16) per 100,000 person-years, or approximately 1...
8 mar 2022 · Levonorgestrel intrauterine sustained release system (LNG-IUS) is an intrauterine hormonal contraceptive device. Breast cancer (BC) was the most common type of cancer in women in the world in 2020. The relationship between LNG-IUS and BC is controversial.
This analysis used nationwide Danish registries to identify breast cancer cases among girls and women aged 15-49 years and filled prescriptions for HC (including the levonorgestrel-intrauterine system [LNG-IUS]). The analysis included 11,517 invasive breast cancers among 1.8 million Danish girls and women.
Our objective was to conduct a systematic review and meta-analysis of the literature on the risk of breast cancer development in women using the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS).
21 mar 2023 · Overall, 44% (4,195/9,498) of women with breast cancer and 39% (7,092/18,171) of matched controls had a hormonal contraceptive prescription an average of 3.1 (SD 3.7) years before breast cancer diagnosis (or equivalent date for controls).
18 lis 2020 · A total of 1085 breast cancer cases were found among the 5346 LNG-IUS users, and 4028 cases of breast cancer were found among the 20,219 controls. The results did not give any indication that LNG-IUS use is associated with an increased risk of breast cancer in women younger than 50 years of age.
